Cargando…
Effective Rituximab Treatment in Patients with Neuromyelitis Optica Spectrum Disorders Compared with Azathioprine and Mycophenolate
INTRODUCTION: As an autoimmune central nervous system disease characterized by inflammation and demyelination, neuromyelitis optica (NMO) has been extensively investigated. A specific antigenic target, astrocytic water channel aquaporin-4 (AQP4) has already been identified, and it can be recognized...
Autores principales: | Yang, Yang, Chen, Lifeng, Wu, Lei, Yao, Jiarui, Wang, Na, Su, Xiaoqing, Li, Dongmei, Han, Lina, Wu, Weiping, Huang, Dehui, Jiang, Tianyu, Wang, Zhenfu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8857340/ https://www.ncbi.nlm.nih.gov/pubmed/34797551 http://dx.doi.org/10.1007/s40120-021-00298-5 |
Ejemplares similares
-
Relationship between Azathioprine metabolites and therapeutic efficacy in Chinese patients with neuromyelitis optica spectrum disorders
por: Li, Xindi, et al.
Publicado: (2017) -
Rituximab in Neuromyelitis Optica Spectrum Disorders: Our Experience
por: Jade, Jui Dilip, et al.
Publicado: (2017) -
Cost effectiveness of rituximab and mycophenolate mofetil for neuromyelitis optica spectrum disorder in Thailand: Economic evaluation and budget impact analysis
por: Aungsumart, Saharat, et al.
Publicado: (2020) -
Comparison of Long-Term Use of Low Dose Rituximab and Mycophenolate Mofetil in Chinese Patients With Neuromyelitis Optica Spectrum Disorder
por: Lin, Jie, et al.
Publicado: (2022) -
Rituximab monitoring and redosing in pediatric neuromyelitis optica spectrum disorder
por: Nosadini, Margherita, et al.
Publicado: (2016)